Ethyl pyruvate ameliorates 3-nitropropionic acid-induced striatal toxicity through anti-neuronal cell death and anti-inflammatory mechanisms

Brain, Behavior, and Immunity

Volumn 38, Issue , 2014, Pages 151-165

  Jang, Minhee ^a   Lee, Min Jung ^a   Cho, Ik Hyun ^a  

^a Kyung Hee University   (South Korea)

Author keywords

3 Nitropropionic acid; Ethyl pyruvate; Huntington's disease; Microglia; Mitogen activated protein kinases; Nuclear factor kappa B

Indexed keywords

3 NITROPROPIONIC ACID; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPROTECTIVE AGENT; PYRROLIDINE DITHIOCARBAMATE; PYRUVIC ACID ETHYL ESTER; SUCCINATE DEHYDROGENASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ETHYL PYRUVATE; MESSENGER RNA; PYRUVIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR; 3-NITROPROPIONIC ACID; ANTIINFLAMMATORY AGENT; NITRO DERIVATIVE; PROPIONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DOWN REGULATION; HISTOLOGY; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; INTOXICATION; LETHALITY; MALE; MICROGLIA; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL TISSUE; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; NERVE CELL NECROSIS; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DRUG EFFECTS; INFLAMMATION; METABOLISM; SIGNAL TRANSDUCTION; TOXICITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; NEUROPROTECTIVE AGENTS; NITRO COMPOUNDS; PROPIONATES; PYRUVATES; SIGNAL TRANSDUCTION;

EID: 84898547300     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2014.01.015     Document Type: Article

References (67)

1. Apostol B.L., Illes K., Pallos J., Bodai L., Wu J., Strand A., Schweitzer E.S., Olson J.M., Kazantsev A., Marsh J.L., Thompson L.M. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum. Mol. Genet. 2006, 15:273-285.
2. Bezprozvanny I., Hayden M.R. Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophys. Res. Commun. 2004, 322:1310-1317.
3. Bjorkqvist M., Wild E.J., Thiele J., Silvestroni A., Andre R., Lahiri N., Raibon E., Lee R.V., Benn C.L., Soulet D., Magnusson A., Woodman B., Landles C., Pouladi M.A., Hayden M.R., Khalili-Shirazi A., Lowdell M.W., Brundin P., Bates G.P., Leavitt B.R., Moller T., Tabrizi S.J. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 2008, 205:1869-1877.
4. Block M.L., Hong J.S. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem. Soc. Trans. 2007, 35:1127-1132.
5. Blum D., Gall D., Cuvelier L., Schiffmann S.N. Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. Neuroreport 2001, 12:1769-1772.
6. Bortolatto C.F., Jesse C.R., Wilhelm E.A., Chagas P.M., Nogueira C.W. Organoselenium bis selenide attenuates 3-nitropropionic acid-induced neurotoxicity in rats. Neurotox. Res. 2013, 23:214-224.
7. Brouillet E., Guyot M.C., Mittoux V., Altairac S., Condé F., Palfi S., Hantraye P. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J. Neurochem. 1998, 70:794-805.
8. Brouillet E., Jacquard C., Bizat N., Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem. 2005, 95:1521-1540.
9. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 1997, 41:646-653.
10. Cai B., Deitch E.A., Ulloa L. Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm. 2010, 2010:642462.
11. Cheng B.Q., Liu C.T., Li W.J., Fan W., Zhong N., Zhang Y., Jia X.Q., Zhang S.Z. Ethyl pyruvate improves survival and ameliorates distant organ injury in rats with severe acute pancreatitis. Pancreas 2007, 35:256-261.
12. Cho I.H., Hong J., Suh E.C., Kim J.H., Lee H., Lee J.E., Lee S., Kim C.H., Kim D.W., Jo E.K., Lee K.E., Karin M., Lee S.J. Role of microglial IKKbeta in kainic acid-induced hippocampal neuronal cell death. Brain 2008, 131:3019-3033.
13. Cho I.H., Kim S.W., Kim J.B., Kim T.K., Lee K.W., Han P.L., Lee J.K. Ethyl pyruvate attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. J. Neurosci. Res. 2006, 84:1505-1511.
14. Choi J.S., Lee M.S., Jeong J.W. Ethyl pyruvate has a neuroprotective effect through activation of extracellular signal-regulated kinase in Parkinson's disease model. Biochem. Biophys. Res. Commun. 2010, 394:854-858.
15. Damiano M., Galvan L., Deglon N., Brouillet E. Mitochondria in Huntington's disease. Biochim. Biophys. Acta 2010, 1802:52-61.
16. Dedeoglu A., Ferrante R.J., Andreassen O.A., Dillmann W.H., Beal M.F. Mice overexpressing 70-kDa heat shock protein show increased resistance to malonate and 3-nitropropionic acid. Exp. Neurol. 2002, 176:262-265.
17. Fan J., Gladding C.M., Wang L., Zhang L.Y., Kaufman A.M., Milnerwood A.J., Raymond L.A. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease. Neurobiol. Dis. 2012, 45:999-1009.
18. Fernagut P.O., Diguet E., Stefanova N., Biran M., Wenning G.K., Canioni P., Bioulac B., Tison F. Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. Neuroscience 2002, 114:1005-1017.
19. Ferrer I., Blanco R., Carmona M. Differential expression of active, phosphorylation-dependent MAP kinases, MAPK/ERK, SAPK/JNK and p38, and specific transcription factor substrates following quinolinic acid excitotoxicity in the rat. Brain Res. Mol. Brain Res. 2001, 94:48-58.
20. Fink M.P. Ethyl pyruvate: a novel anti-inflammatory agent. J. Intern. Med. 2007, 261:349-362.
21. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 2008, Elsevier Academic Press, San Iego.
22. Garcia M., Charvin D., Caboche J. Expanded huntingtin activates the c-Jun terminal kinase/c-Jun pathway prior to aggregate formation in striatal neurons in culture. Neuroscience 2004, 127:859-870.
23. Garcia M., Vanhoutte P., Pages C., Besson M.J., Brouillet E., Caboche J. The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module. J. Neurosci. 2002, 22:2174-2184.
24. Gianfriddo M., Melani A., Turchi D., Giovannini M.G., Pedata F. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol. Dis. 2004, 17:77-88.
25. Gokce O., Runne H., Kuhn A., Luthi-Carter R. Short-term striatal gene expression responses to brain-derived neurotrophic factor are dependent on MEK and ERK activation. PLoS One 2009, 4:e5292.
26. Haddad J.J. N-methyl-d-aspartate (NMDA) and the regulation of mitogen-activated protein kinase (MAPK) signaling pathways: a revolving neurochemical axis for therapeutic intervention?. Prog. Neurobiol. 2005, 77:252-282.
27. Harper S.J., Wilkie N. MAPKs: new targets for neurodegeneration. Expert Opin. Ther. Targets 2003, 7:187-200.
28. Hetman M., Gozdz A. Role of extracellular signal regulated kinases 1 and 2 in neuronal survival. Eur. J. Biochem. 2004, 271:2050-2055.
29. Hsieh C.C., Rosenblatt J.I., Papaconstantinou J. Age-associated changes in SAPK/JNK and p38 MAPK signaling in response to the generation of ROS by 3-nitropropionic acid. Mech. Ageing Dev. 2003, 124:733-746.
30. Huang Q.Y., Wei C., Yu L., Coelho J.E., Shen H.Y., Kalda A., Linden J., Chen J.F. Adenosine A2A receptors in bone marrow-derived cells but not in forebrain neurons are important contributors to 3-nitropropionic acid-induced striatal damage as revealed by cell-type-selective inactivation. J. Neurosci. 2006, 26:11371-11378.
31. Huh S.H., Chung Y.C., Piao Y., Jin M.Y., Son H.J., Yoon N.S., Hong J.Y., Pak Y.K., Kim Y.S., Hong J.K., Hwang O., Jin B.K. Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease. J. Immunol. 2011, 187:960-969.
32. Jang M., Lee M.J., Kim C.S., Cho I.H. Korean red ginseng extract attenuates 3-nitropropionic acid-induced Huntington's-like symptoms. Evid. Based Comp. Alternat Med. 2013, 2013:237207.
33. Jung J.S., Shin J.A., Park E.M., Lee J.E., Kang Y.S., Min S.W., Kim D.H., Hyun J.W., Shin C.Y., Kim H.S. Anti-inflammatory mechanism of ginsenoside Rh1 in lipopolysaccharide-stimulated microglia: critical role of the protein kinase A pathway and hemeoxygenase-1 expression. J. Neurochem. 2010, 115:1668-1680.
34. Juo P., Kuo C.J., Reynolds S.E., Konz R.F., Raingeaud J., Davis R.J., Biemann H.P., Blenis J. Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases. Mol. Cell. Biol. 1997, 17:24-35.
35. Kao K.K., Fink M.P. The biochemical basis for the anti-inflammatory and cytoprotective actions of ethyl pyruvate and related compounds. Biochem. Pharmacol. 2010, 80:151-159.
36. Khoshnan A., Ko J., Watkin E.E., Paige L.A., Reinhart P.H., Patterson P.H. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J. Neurosci. 2004, 24:7999-8008.
37. Kim H.S., Cho I.H., Kim J.E., Shin Y.J., Jeon J.H., Kim Y., Yang Y.M., Lee K.H., Lee J.W., Lee W.J., Ye S.K., Chung M.H. Ethyl pyruvate has an anti-inflammatory effect by inhibiting ROS-dependent STAT signaling in activated microglia. Free Radical Biol. Med. 2008, 45:950-963.
38. Kim J.B., Yu Y.M., Kim S.W., Lee J.K. Anti-inflammatory mechanism is involved in ethyl pyruvate-mediated efficacious neuroprotection in the postischemic brain. Brain Res. 2005, 1060:188-192.
39. Kim S.W., Jeong J.Y., Kim H.J., Seo J.S., Han P.L., Yoon S.H., Lee J.K. Combination treatment with ethyl pyruvate and aspirin enhances neuroprotection in the postischemic brain. Neurotox. Res. 2010, 17:39-49.
40. Kumar P., Kalonia H., Kumar A. Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats: protective effect of licofelone. Br. J. Pharmacol. 2011, 164:644-654.
41. Kumar P., Kumar A. Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunctions in rat brain. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:100-108.
42. Landis S.C., Amara S.G., Asadullah K., Austin C.P., Blumenstein R., Bradley E.W., Crystal R.G., Darnell R.B., Ferrante R.J., Fillit H., Finkelstein R., Fisher M., Gendelman H.E., Golub R.M., Goudreau J.L., Gross R.A., Gubitz A.K., Hesterlee S.E., Howells D.W., Huguenard J., Kelner K., Koroshetz W., Krainc D., Lazic S.E., Levine M.S., Macleod M.R., McCall J.M., Moxley R.T., Narasimhan K., Noble L.J., Perrin S., Porter J.D., Steward O., Unger E., Utz U., Silberberg S.D. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012, 490:187-191.
43. Lee E.J., Kim H.S. Inhibitory mechanism of MMP-9 gene expression by ethyl pyruvate in lipopolysaccharide-stimulated BV2 microglial cells. Neurosci. Lett. 2011, 493:38-43.
44. Lee M.J., Jang M., Jung H.S., Kim S.H., Cho I.H. Ethyl pyruvate attenuates formalin-induced inflammatory nociception by inhibiting neuronal ERK phosphorylation. Mol. Pain 2012, 8:40.
45. Leegwater-Kim J., Cha J.H. The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration. NeuroRx 2004, 1:128-138.
46. Liu Y.F., Dorow D., Marshall J. Activation of MLK2-mediated signaling cascades by polyglutamine-expanded huntingtin. J. Biol. Chem. 2000, 275:19035-19040.
47. Lobsiger C.S., Cleveland D.W. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat. Neurosci. 2007, 10:1355-1360.
48. Marcy, E.E.M.M., Ambrose, C.M., Duyao, M.P., Myers, R.H., Lakshmi Srinidhi, Taylor, S.A., James, M., Groot, N., MacFarlane, H., Jenkins, B., Anderson, M.A., Wexler, N.S., Gusella, J.F., 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72, 971-983.
49. Mattson M.P., Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. J. Clin. Invest. 2001, 107:247-254.
50. Mestre C., Pelissier T., Fialip J., Wilcox G., Eschalier A. A method to perform direct transcutaneous intrathecal injection in rats. J. Pharmacol. Toxicol. Methods 1994, 32:197-200.
51. Napolitano M., Costa L., Palermo R., Giovenco A., Vacca A., Gulino A. Protective effect of pioglitazone, a PPARgamma ligand, in a 3 nitropropionic acid model of Huntington's disease. Brain Res. Bull. 2011, 85:231-237.
52. Park J.S., Park E.M., Kim D.H., Jung K., Jung J.S., Lee E.J., Hyun J.W., Kang J.L., Kim H.S. Anti-inflammatory mechanism of ginseng saponins in activated microglia. J. Neuroimmunol. 2009, 209:40-49.
53. Pavese N., Gerhard A., Tai Y.F., Ho A.K., Turkheimer F., Barker R.A., Brooks D.J., Piccini P. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006, 66:1638-1643.
54. Perrin V., Dufour N., Raoul C., Hassig R., Brouillet E., Aebischer P., Luthi-Carter R., Deglon N. Implication of the JNK pathway in a rat model of Huntington's disease. Exp. Neurol. 2009, 215:191-200.
55. Qin Z.H., Chen R.W., Wang Y., Nakai M., Chuang D.M., Chase T.N. Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum. J. Neurosci. 1999, 19:4023-4033.
56. Rangone H., Poizat G., Troncoso J., Ross C.A., MacDonald M.E., Saudou F., Humbert S. The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur. J. Neurosci. 2004, 19:273-279.
57. Roze E., Betuing S., Deyts C., Marcon E., Brami-Cherrier K., Pages C., Humbert S., Merienne K., Caboche J. Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death. Faseb. J. 2008, 22:1083-1093.
58. Ryu J.K., Kim S.U., McLarnon J.G. Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease. Exp. Neurol. 2004, 187:150-159.
59. Shen H., Hu X., Liu C., Wang S., Zhang W., Gao H., Stetler R.A., Gao Y., Chen J. Ethyl pyruvate protects against hypoxic-ischemic brain injury via anti-cell death and anti-inflammatory mechanisms. Neurobiol. Dis. 2010, 37:711-722.
60. Song M., Kellum J.A., Kaldas H., Fink M.P. Evidence that glutathione depletion is a mechanism responsible for the anti-inflammatory effects of ethyl pyruvate in cultured lipopolysaccharide-stimulated RAW 264.7 cells. J. Pharmacol. Exp. Ther. 2004, 308:307-316.
61. Su X., Wang H., Zhu L., Zhao J., Pan H., Ji X. Ethyl pyruvate ameliorates intracerebral hemorrhage-induced brain injury through anti-cell death and anti-inflammatory mechanisms. Neuroscience 2013, 245:99-108.
62. Sugino T., Nozaki K., Hashimoto N. Activation of mitogen-activated protein kinases in gerbil hippocampus with ischemic tolerance induced by 3-nitropropionic acid. Neurosci. Lett. 2000, 278:101-104.
63. Tai Y.F., Pavese N., Gerhard A., Tabrizi S.J., Barker R.A., Brooks D.J., Piccini P. Imaging microglial activation in Huntington's disease. Brain Res. Bull. 2007, 72:148-151.
64. Varma H., Cheng R., Voisine C., Hart A.C., Stockwell B.R. Inhibitors of metabolism rescue cell death in Huntington's disease models. Proc. Natl. Acad. Sci. USA 2007, 104:14525-14530.
65. Wang Q., Ding Q., Zhou Y., Gou X., Hou L., Chen S., Zhu Z., Xiong L. Ethyl pyruvate attenuates spinal cord ischemic injury with a wide therapeutic window through inhibiting high-mobility group box 1 release in rabbits. Anesthesiology 2009, 110:1279-1286.
66. Xu X.H., Chen Q., Chen Y., Lv L.X., Zhu C.Q., Dai H.L., Qian J.Q. Effect of ethyl pyruvate on expression of inflammatory factors and mitogen-activated protein kinase proteins in renal ischemic/reperfusion injury in BABL/c mice. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2010, 22:750-753.
67. Yu Y.M., Kim J.B., Lee K.W., Kim S.Y., Han P.L., Lee J.K. Inhibition of the cerebral ischemic injury by ethyl pyruvate with a wide therapeutic window. Stroke 2005, 36:2238-2243.